Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Maintains Miniscule Melamine Levels Pose No Risk

This article was originally published in The Tan Sheet

Executive Summary

FDA revised its interim safety and risk assessment for the independent presence of melamine or any one of its analogs in infant formula, saying any amount of one such substance below 1 part per million does not raise public health concerns

You may also be interested in...



Mead Johnson Looks City To City In Chinese Expansion Strategy

A disciplined growth strategy enables Mead Johnson Nutrition to expand its footprint in China and other emerging markets, as lower U.S. birth rates continue to dampen the firm's domestic business

Mead Johnson Looks City To City In Chinese Expansion Strategy

A disciplined growth strategy enables Mead Johnson Nutrition to expand its footprint in China and other emerging markets, as lower U.S. birth rates continue to dampen the firm's domestic business.

Mead Johnson Looks City To City In Chinese Expansion Strategy

A disciplined growth strategy enables Mead Johnson Nutrition to expand its footprint in China and other emerging markets, as lower U.S. birth rates continue to dampen the firm's domestic business.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS102380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel